1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Preleukemia in 1 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Preleukemia: Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duraj, J | 1 |
| Kovacikova, M | 1 |
| Sedlak, J | 1 |
| Koppel, J | 1 |
| Sobel, A | 1 |
| Chorvath, B | 1 |
1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Preleukemia
| Article | Year |
|---|---|
The protein kinase C inhibitor H7 blocks phosphorylation of stathmin during TPA-induced growth inhibition of human pre-B leukemia REH6 cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Burkitt Lymphoma; Calmodulin; Cell Cycle; Cell Divisi | 1995 |